



## BRONCHOPULMONARY INFECTION BY LOPHOMONAS BLATTARUM- AN EMERGING DISEASE OR A SPECULATIVE MYTH?

### Microbiology

**Vandana Sardana\*** MD, Associate Professor, Department of Microbiology, Shri Ram Murti Smarak Institute of Medical Sciences, Bareilly- 243202. \*Corresponding Author

**Saumya Srivastava** Senior Resident, Department of Microbiology, AIIMS, Jodhpur, Rajasthan.

**Sameer R. Verma** MD, Professor, Department of Radiodiagnosis, Shri Ram Murti Smarak Institute of Medical Sciences, Bareilly-243202.

### ABSTRACT

**Introduction:** Lophomonas blattarum is a multi flagellated protozoan, which is the endocommensal of the intestinal tracts of termites and cockroaches. Human infections with Lophomonas blattarum are rare but the association of Lophomonas and respiratory pathology, especially in immunocompromised individuals has recently gained concern. **Aims & Objectives:** i) To determine the frequency of bronchopulmonary lophomoniasis in clinically diagnosed cases of respiratory tract infections. ii) To identify the risk factors associated with it. **Methods:** A retrospective data of three years was collected to study the number of bronchoalveolar lavage fluids showing the presence of Lophomonas blattarum, submitted to the Department of Microbiology. Lophomonas blattarum was identified in bronchoalveolar lavage fluid by direct microscopic examination of wet mount and/or Giemsa stained smear. **Results:** A total number of 1053 bronchoalveolar lavage fluids were received from clinically diagnosed/suspected cases of respiratory tract infections. the frequency of occurrence of Lophomonas blattarum in BAL fluids was found to be 1.14% (12/1053). Amongst the positive cases, predominant age group affected was  $\geq 61$  years, followed by 31-40 years, and females outnumbered males with the ratio of 4.5:1. Bronchopulmonary Lophomonas infection was most commonly associated with diabetes (41.7%), followed by prolonged corticosteroid therapy (33.3%), chronic smoking (16.7%) and cytotoxic chemotherapy (8.3%). **Conclusions:** The observation of Lophomonas blattarum, in BAL fluids, under light microscopy, in patients who do not respond to antibiotics, but show satisfactory improvement with antiprotozoal therapy, can be labeled as bronchopulmonary lophomoniasis. The development of molecular methods to resolve the issue regarding the confusion with other structures such as ciliated bronchial cells and other endocommensals of gut of the termites, would be promising.

### KEYWORDS

BAL, Bronchopulmonary lophomoniasis, Lophomonas blattarum, Cockroaches

### INTRODUCTION:

Lophomonas blattarum is a multiflagellated protozoan, which inhabits the hindgut of termites and cockroaches, belonging to the Lophomonas sub order, Hypermastigida order, phylum Parabasalia.<sup>1,2,3,4</sup> The first case of pulmonary infection by L. blattarum was identified in 1993 in China by Chen and Mengsin, and thereafter more than 100 cases of bronchopulmonary lophomoniasis have been reported since 1993.<sup>5,6,7</sup> The cockroaches, such as Periplaneta Americana and Blattellagermanica, excrete the parasite in the feces and once eliminated, it forms cyst that remains in the environment.<sup>3,8</sup> Although the human infection by L. blattarum is rare, it could cause pulmonary infection in susceptible patients through the inhalation of dust containing the cyst.<sup>8,9</sup> As far as its pathogenic mechanisms are concerned, certain proteases have been identified that are involved in cyto-adherence, epithelial barrier rupture, apoptosis.<sup>10</sup>

Pulmonary protozoal infections are increasingly being recognized in this current scenario.<sup>11</sup> This rise may be due to an increasing proportion of the population having compromised immune status. Immunocompromised function in the respiratory tract could be due to infection with the human immunodeficiency virus, long-term use of steroids and other immunosuppressive drugs, malignancies, systemic illness, or chronic respiratory pathology.<sup>12</sup> A proportion of the rise in protozoal infections is due to multiflagellate Lophomonas blattarum.<sup>13,14</sup> Although L. blattarum is uncommon but has a potential to cause pulmonary infections and respiratory symptoms.<sup>14-17</sup> The most common symptoms are fever, cough, expectoration, and shortness of breath, and the radiological findings may show pneumonia, bronchiectasis, pulmonary abscesses, and pleural effusion.<sup>18</sup> The protozoan has been also reported in patients with severe pulmonary disease<sup>18</sup> and asthma.<sup>19,20</sup> The identification of L. blattarum is based on the morphological features under light microscopy using fresh and stained samples including sputum, bronchoalveolar lavages, bronchial brushings and tracheal aspirates. Multiflagellate protozoa are difficult to differentiate from ciliated bronchial epithelial cells, under light microscopy, and their misidentification is an important issue.<sup>21</sup> L. blattarum is round to oval,<sup>20-60</sup>  $\mu\text{m}$  in diameter, and has a double tuft of flagella at the anterior end.<sup>22,23</sup> Electron microscopy provides ultrastructure of L. blattarum and its differentiation from bronchial ciliated epithelial cells. The funnel shaped calyx, axial filament, and perinuclear tubules are special structures of L. blattarum.<sup>24</sup>

To the best of our knowledge, limited data is available on pulmonary lophomoniasis in western Uttar Pradesh, which has prompted us to carry out the present study in this belt.

### Materials And Method:

The retrospective study was conducted in a tertiary care hospital, from April 2016 to March 2019. Our laboratory receives bronchoalveolar lavage fluids for microbiological investigations, from patients with a clinical diagnosis of lower respiratory infections.

The study group included all the patients irrespective of age and gender, whose BAL fluids had been received in the laboratory.

### Sample Processing:

BAL fluids were processed for direct microscopy and for culture as per standard techniques.<sup>25,26</sup>

BAL fluids were centrifuged at 3000 rpm for 15 minutes and the deposits obtained were processed as follows as per the requisition such as:

1. Wet mount/10% Potassium hydroxide (KOH) mount
2. Gram Staining
3. Ziehl Neelsen (ZN) staining- Smears were stained by Ziehl Neelsen (ZN) staining to look for beaded acid-fast bacilli.
4. Bacterial culture aerobic- Samples were inoculated on to Blood agar, Chocolate agar, MacConkey agar. Plates were incubated at 37°C for 24 hours. Any growth obtained was identified as per standard protocol. If there was no growth, culture plates were reincubated for another 24 hours.
5. Culture for Mycobacterium tuberculosis by automated liquid culture (BacT/ALERT 3D, BioMerieux):
6. Fungal culture- Samples were inoculated onto Sabouraud dextrose agar (SDA) with antibiotics but without cycloheximide, and incubated at 25°C and 37°C. The culture tubes were examined at 3-4 days interval for growth. The isolates were identified by as per the standard mycological techniques.

### RESULTS:

A total number of 1053 bronchoalveolar lavage fluids received from clinically diagnosed cases of lower respiratory tract infections were subjected to microbiological investigations. Out of 1053 cases, 220 were found to be negative for bacterial/ tubercular/ fungal etiology. Among the remaining 833 cases, 754 BAL fluids were positive for

bacterial growth, 71 showed fungal growth and 8 cases were positive for *Mycobacterium tuberculosis*.

Out of total of 220 culture sterile BAL fluids, in 12 samples multilagellated protozoan *Lophomonas blattarum* was identified as an incidental finding in wet mount, which was further subjected to identification by Giemsa staining. Thus, the frequency of occurrence of *Lophomonas blattarum* in BAL fluids in clinically diagnosed cases of lower respiratory tract infections was found to be 1.14%(12/1053).

Amongst the positive cases,(n=12). predominant age group affected was ≥ 61 years, followed by 31-40 years, and females outnumbered males with 4.5:1 (Table 1).

Bronchoulmonary *Lophomonas* infection was most commonly associated with diabetes (41.7 %), followed by prolonged corticosteroid therapy (33.3 %), chronic smoking (16.7 %) and cytotoxic chemotherapy(8.3%)(Table 2).

Computed axial tomography-high resolution (HRCT) chest findings in all the cases of bronchopulmonary lophomoniasis were consistent with either consolidation or brochiectatic changes, predominantly consolidation. Bilateral pulmonary consolidation was found in 50% cases of bronchopulmonary lophomoniasis, followed by right lobe consolidation (25% cases), left lobe consolidation (16.7% cases ) and right lobe bronchiectasis (8.3% cases)(Table 3).

**Table 1:Age and gender wise distribution of cases of bronchopulmonary lophomoniasis (n= 12)**

Age (in years)	Positive cases		
	Number of positive cases	Male	Female
41-50	1	1	0
51-60	5	3	2
≥ 61	6	4	2
Total	12	8	4

**Table 2: Risk factors associated with cases of bronchopulmonary lophomoniasis (n= 12)**

Risk factor	Positive cases (n=12)	Percentage (%)
Diabetes mellitus	5	41.7
Prolonged steroid therapy	4	33.3
Chronic smoking	2	16.7
Cytotoxic chemotherapy for underlying breast carcinoma	1	8.3

**Table 3: Radiological findings associated with cases of bronchopulmonary lophomoniasis (n= 12)**

Chest computed tomography findings	Number of cases	Percentage of cases (%)
Bilateral pulmonary consolidation	6	50
Right lobe pulmonary consolidation	3	25
Left lobe pulmonary consolidation	2	16.7
Right lobe bronchiectasis	1	8.3

**DISCUSSION:**

*Lophomonas blattarum*(LB) is being considered and recognized an emerging parasite that can cause respiratory tract infection. *L. blattarum* is a multilagellated protozoan parasite living in the intestinal tracts of termites and cockroaches.<sup>1</sup> More than 100 cases of *L. blattarum* infection have been reported since the first case emerged in 1993.<sup>7</sup> The vast majority of studies reported *L. blattarum* infection based on morphology under a light microscope.<sup>15,27,28</sup>

In the present study the frequency of bronchopulmonary lophomoniasis in clinically diagnosed cases of lower respiratory tract infections was found to be 1.14%.

Infection caused by the multilagellated protozoan *L. blattarum* has been reported by various authors and its presence in respiratory secretions, has been identified.<sup>15,27,28</sup>

*L. blattarum* can be detected in sputum smears, BAL, or biopsy smears.<sup>8</sup> There are reports on lophomonas pulmonary infection from China,<sup>12,13,15</sup> Turkey,<sup>16</sup> Spain,<sup>17</sup> Peru,<sup>19</sup> India<sup>20</sup> and Iran.<sup>4,30,31</sup> As per the literature, 137 cases have been reported from 1993 to 2014.<sup>8</sup> Human pulmonary infection with *L. blattarum* has been also reported in

patients with bronchopneumonia, severe pulmonary disease<sup>7</sup> and adult patients with asthma<sup>14,32</sup>

In our set up, amongst the positive cases of bronchpulmonary *L. blattarum* infection (n=12), predominant age group affected was ≥ 61years, followed by 31-40 years. The occurrence of *Lophomonas* infection in elderly patients reflects its association with weakened immune system in aging process. Females outnumbered males with the ratio of 4.5:1 (Table 1).

Bronchoulmonary *Lophomonas* infection, in the present study was most commonly associated with diabetes (41.7 %), followed by prolonged corticosteroid therapy (33.3 %), chronic smoking (16.7 %) and cytotoxic chemotherapy (8.3 %).(Table 2).

The majority of these *Lophomonas* pulmonary infections have been reported in immunocompromised patients in China.<sup>12,13,15</sup> A case of a patient having dual infection with tuberculosis has been reported from India.<sup>33</sup>

Although, most of the cases been reported in immunocompromised patients,<sup>6,7</sup> a case has been reported in immunocompetent young male in Mumbai, India by Tyagi R et al. in<sup>2016,34</sup>

Clues to *L. blattarum* infection include patients who are immunocompromised or have history of prolonged use of immunosuppressants due to underlying disease, marked peripheral eosinophilia, clinical features of a pulmonary infection, and poor response to antibiotics.<sup>8</sup> Authors have also reported that patients subjected to solid organ or hematopoietic cell transplants developed the pulmonary *L. blattarum* infection, during the course of illness.<sup>17,22</sup>

In our study, computed tomography chest findings in all the cases of bronchopulmonary lophomoniasis were consistent with either consolidation or brochiectatic changes. Bilateral pulmonary consolidation was found in 50% cases of bronchopulmonary lophomoniasis, followed by right lobe consolidation (25% cases), left lobe consolidation (16.7% cases ) and right lobe bronchiectasis (8.3% cases).

The clinical signs and symptoms of *L. blattarum* pulmonary infection are generally nonspecific in majority of the cases, and the clinical findings of pneumonia are the same as with other etiological agents.<sup>35</sup>

Under light microscopy, it is difficult to differentiate *Lophomonas blattarum* from ciliated bronchial epithelial cells. *L. blattarum* was first described in 1860 by S. Stein from the gut of the cockroach *Blatta orientalis*. It was, also observed in the hindgut of the other cockroaches such as *Periplaneta Americana* and *Blatella Germanica*.<sup>5</sup>

A detailed morphologic description of *L. blattarum* under a light microscope was undertaken by Brugerolle and Lee in 1911.<sup>36</sup> The presence of *L. blattarum* could be determined for being motile with a tuft of flagella extending from the anterior end It possesses about 50 or more flagella of different lengths. It has a piriform structure with diameter ranging from 20 to 60 μ depending on the number of vacuoles it possesses. Golgi body, mitochondria and other organelles are present in its cytoplasm.<sup>18,37</sup>

Ciliated epithelial cells are conical or columnar in shape, having round-oval nucleus at the basal end and a marked terminal bar at the apical end of the cell with regular, unidirectional tuft of cilia inserted into the terminal bar.<sup>23,37</sup>

Because many of these flagellates cannot be cultivated, their identification by light and electron microscopy is important. The development of molecular methods for identification of *L. blattarum* becomes essential<sup>38</sup>

In our study, all the cases of bronchopulmonary lophomoniasis did not show any clinical improvement with broad spectrum antibiotics. All these cases had responded well to metronidazole . Metronidazole was administered intravenously with the loading dose of 15mg/kg, followed by oral metronidazole 500mg thrice a day for ten days. All the cases showed good clinical response.

Metronidazole have been reported in various studies as the most


effective treatment for the *Lophomonas* infection worldwide.<sup>18,33,34,39-41</sup>

### CONCLUSION:


We consider that the finding of *Lophomonas blattarum*, a multiflagellated protozoon, under light microscopy, in symptomatic patients, who do not respond to antibiotics, but show satisfactory improvement with antiprotozoal therapy, can be described as bronchopulmonary lophomoniasis. This infection should be recognized as a potentially important, especially in the patients with compromised immunity and risk factors. We would emphasize the need of the development of a technique to culture the organism or the use of molecular methods to resolve the issue regarding the confusion with other structures such as ciliated bronchial cells, and other endocommensals of gut of the termites.

### LIMITATION:


Development of molecular techniques would have helped distinguish between ciliated bronchial cells and the protozoa. The findings under electron microscopy would have also been noteworthy.



**Image 1: *Lophomonas blattarum* in wet mount of BAL fluid (blue arrow)**



**Image 2: *Lophomonas blattarum* in Giemsa stained smear of BAL fluid (black arrow)**



**Image 3: CT chest a) Lung window and b) Mediastinal window axial images reveal bilateral lung consolidations**

### REFERENCES:

- Mu XL, Shang Y, Zheng SY, Zhou B, Yu B, Dong XSet al. A study on the differential diagnosis of ciliated epithelial cells from *Lophomonas blattarum* in bronchoalveolar lavage fluid (In Chinese). *Chin J Tuberc Respir Dis.* 2013;36:646-50. doi: 10.3760/cma.j.issn.1001-0939.2013.09.003.
- González Saldaña N, Otero Mendoza FJ, Rivas Larrauri F, Galvis Trujillo DM, Venegas Montoya E, De La Garza EA, Juárez Olguín H. Bronchopulmonary infection by *Lophomonas blattarum* in a pediatric patient after hematopoietic progenitor cell transplantation: first report Mexico. *J Thorac Dis.* 2017;9(10):E899-E902. doi: 10.21037/jtd.2017.09.19.
- Carpenter UJ, Chow L, heeding PJ. Morphology, phylogeny, and diversity of *Trichonympha* (Parabasalida: I-hypermastigida) of the wood-feeding cockroach *Cryptocercus punctulatus*. *J Eukaryot Microbiol.* 2009;56:305-31.
- Martinez-Giron R., van Woerden HC, Doganci, L. *Lophomonas* misidentification in bronchoalveolar lavages. *Intern Med.* 2011; 50:2721-2723.

- Zhang X, Xu L, Wang LL, Liu S, Li J, Wang X. Bronchopulmonary infection with *Lophomonas blattarum*: a case report and literature review. *J Int Med Res.* 2011;39:944-9.
- Adl SM, Simpson AG, Farmer MA, Andersen RA, Andersen OR, Barta JR et al. The new higher level classification of eukaryotes with emphasis on the taxonomy of protists. *J Eukaryot Microbiol.* 2005;52:399-451.
- Chen SX, Meng ZX. Report on one case of *Lophomonas blattarum* in the respiratory tract. *Chinese J Parasitol Parasit Dis.* 1993;11:28.
- Xue J, Li YL, Yu XM, et al. Bronchopulmonary infection of *Lophomonas blattarum*: a case and literature review. *Korean J Parasitol.* 2014;52:521-5.
- He Q, Chen X, Lin B, Qu L, Wu J, Chen J. Late onset pulmonary *Lophomonas blattarum* infection in renal transplantation: a report of two cases. *Intern Med.* 2011;50:1039-43.
- Zeng H, Kong X, Chen X, Luo H, Chen P, Chen Y. *Lophomonas blattarum* infection presented as acute exacerbation of chronic obstructive pulmonary disease. *J Thorac Dis.* 2014;6:E73-6.
- Vijayan VK. Is the incidence of parasitic lung diseases increasing, and how may this affect modern respiratory medicine? *Expert Rev Respir Med.* 2009; 3: 339-344.
- Martinez-Giron R, Doganci L, Ribas A. From the 19th century to the 21st, an old dilemma: ciliocytophthoria, multi- flagellated protozoa, or both? *Diagn Cytopathol.* 2008; 36, 609-611.
- Martinez-Giron R, Esteban JG, Ribas A, Doganci, L. Protozoa in respiratory pathology: a review. *Eur Respir J.* 2008; 32, 1354-1370.
- Chen SX, Meng ZX. Bronchopulmonary *Lophomonas blattarum* infection: A case report (In Chinese). *Chin J Parasitol Parasit Dis.* 1993;11:28.
- Yao G, Zhou B, Zeng, L. Imaging characteristics of bronchopulmonary *Lophomonas blattarum* infection: case report and literature review. *J Thorac Imaging.* 2009; 24: 49-51.
- Wu Z, Liu Y. *Blattarum* lophomoniasis: A newly discovered parasitosis. *Journal of Pathogen Biology.* 2010; 7: 21.
- Zhang F, Li YS, Zhang HX, Cai LM, Wu ZX. (2010). Clinical treatment on two cases with bronchopulmonary *Lophomonas blattarum* infection. *Journal of Clin Med Prac.* 2010; 14:83-84.
- Ribas A, Martinez-Giron R, Ponte-Mittelbrum C, Alonso- Cuervo R, Iglesias-Llaca F: Immunosuppression, flagellated protozoa in the human airways and metronidazole: Observations on the state of the art. *Transpl Int.* 2007;20:811-812.
- Martinez-Giron, R, Ribas A, Astudillo-Gonzalez A. Flagellated protozoa in cockroaches and sputum: the unhygienic connection? *Allergy Asthma Proc.* 2007; 28 :608-609.
- Martinez-Giron R, Doganci L. (2010). *Lophomonas blattarum*: a bronchopulmonary pathogen. *Acta Cytol.* 2010; 54 (Suppl):1050-1051.
- Martinez-Giron R, van Woerden H, Ribas-Barcelo A: Could inhaled mite faeces introduce pathogens to the lungs? *Microbes Infect.* 2008;10:452-453.
- Wang Y, Tang Z, Ji S, Zhang Z, Chen J, Cheng Z, Cheng D, Liu Z, Li L: Pulmonary *Lophomonas blattarum* infection in patients with kidney allograft transplantation. *Transpl Int.* 2006;19:1006-1013.
- Brugerolle G, Lee JJ: *Phylum Parabasalia*. In: Lee JJ, Leedale GF: *Bradbury P. (eds.) An Illustrated Guide to the Protozoa*. 2nd edition: Lawrence: Society of Protozoologists; 2000. p. 1196-1250.
- Beams HW, Sekhon SS. Further studies on the fine structure of *Lophomonas blattarum* with special reference to the so-called calyx, axial filament, and parabasal body. *J Ultrastruct Res.* 1969;26:296-315.
- Winn WC, Koneman EW, Allen SD, Procop GW, Ganda WM, Woods GL (eds.) *Koneman's Color Atlas and Textbook of Diagnostic Microbiology*. 6th edition. China: Lippincott Williams and Wilkins; 2006.
- Patricia MT (ed.) *Bailey and Scott's Diagnostic Microbiology*. Thirteenth edition. St. Louis, Missouri: Elsevier; 2014.
- Meng SS, Dai ZF, Wang HC, Li YX, Wei DD, Yang RL, Lin XH. Authenticity of pulmonary *Lophomonas blattarum* infection: A case report. *World J Clin Cases.* 2019;7(1):95-101.
- Martinez-Giron R. Protozoal infections. In: Barrios R, Haque AK. (eds.) *Parasitic diseases of the lungs*. New York: Springer-Verlag; 2013. p. 47-68.
- Zerpa R, Ore E, Patino L, Espinoza YA. (2010). *Lophomonas* sp. in respiratory tract secretions in hospitalized children with severe lung disease. *Rev Peru Med Exp Salud Publica.* 2010; 27: 575-577.
- Berenji F, Parian M, Fata A, Bakhshae M, Fattahi F. First case report of sinusitis with *Lophomonas blattarum* from Iran. *Infect Dis.* 2016;1-2. doi: 10.1155/2016/2614187.
- Ghaffarian N, Bakhtiari E, Berenji F, Nakhaei M, Nakhaei B, F. Jamali-Behnam F, Sayedi SV. The study of *Lophomonas blattarum* infection in children with respiratory symptoms: a descriptive clinical study in North East of Iran. *Int. J. Pediatr.* 2018 ;6 (6) : 7797-7802.
- Wahid W, Fahmi NAA, Salleh AFM, Yasin AM. Bronchopulmonary lophomoniasis: A rare cause of pneumonia in an immunosuppressed host. *Respiratory medicine case reports.* 2019;28:1-3.
- Verma S, Verma G, Singh DV, Mokta J, Negi RS, Jhobta A, Kanga A. Dual infection with pulmonary tuberculosis and *Lophomonas blattarum* in India. *Int J Tuberc Lung Dis.* 2015;19:368-9.
- Tyagi R, Anand KB, Teple K, Negi SR. *Lophomonas blattarum* infection in immunocompetent patient. *Lung India.* 2016;33:667-8.
- Martinez-Giron R, van Woerden HC. *Lophomonas blattarum* and bronchopulmonary disease. *J Med Microbiol.* 2013;62:1641-8.
- Alam-Eldin YH, Abdulaziz AM. Identification criteria of the rare multi-flagellate *Lophomonas blattarum*: comparison of different staining techniques. *Parasitol Res.* 2015;114:3309-14.
- Martinez-Giron R, van Woerden HC. Clinical and immunological characteristics associated with the presence of protozoa in sputum smears. *Diagn. Cytopathol.* 2013;41 (1) : 22-27.
- Ohkuma M, Iida T, Ohtoko K, Yuzawa H, Noda S, Viscogliosi E, Kudo T: Molecular phylogeny of parabasalids inferred from small subunit rRNA sequences, with emphasis on the *Hyper-mastigae*. *Mol Phylogenet Evo.* 2005;35:646-655.
- Yao G, Zeng L, Zhang B, Chang Z. Bronchopulmonary *Lophomonas blattarum* infection: two cases report and literature review. *Zhonghuankezhazhi.* 2008; 47 (8) :176-182.
- Kilimcioglu AA, Havlucu Y, Girginkardesler N, Celik P, Yereki K, Ozbilgin A. Putative bronchopulmonary flagellated protozoa in immunosuppressed patients. *Bio Med Res Int.* 2014; 1-5. <https://doi.org/10.1155/2014/912346>
- Berenji F, Fata A, Vakili V, Sayedi SJ, Abdollahi B, Imanfar H et al. Unexpected high rate of *Lophomonas blattarum* in resistant upper and lower respiratory infection. *Int J Med Res Health Sci.* 2016; 5 (9) :74-80.